Non Small Cell Lung Cancer - PD-L1 inhibitor - CXCL8 overexpression

Association details:

Biomarker:	CXCL8 overexpression
Cancer:	Non Small Cell Lung Cancer
Drug Class:	PD-L1 inhibitor
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

Drug Resist Updat

Title:

Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC

Published date:

07/02/2023

Excerpt:

We found that patients with higher NOX4 and IL-8 expression levels showed a shorter survival time compared to those with lower NOX4 and IL-8 expression levels in response to the anti-PD-L1 therapy.

DOI:

10.1016/j.drup.2023.100987